ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Methylprednisolone: Drug information

Methylprednisolone: Drug information
(For additional information see "Methylprednisolone: Patient drug information" and see "Methylprednisolone: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • DEPO-Medrol;
  • Medrol;
  • P-Care D40 [DSC];
  • P-Care D80 [DSC];
  • SOLU-Medrol
Brand Names: Canada
  • Depo-Medrol;
  • Medrol;
  • SOLU-medrol;
  • Solu-MEDROL;
  • Uni-Med [DSC]
Pharmacologic Category
  • Corticosteroid, Systemic
Dosing: Adult

Note: Dosing: Evidence to support an optimal dose and duration are lacking for most indications; recommendations provided are general guidelines only and primarily based on expert opinion. In general, glucocorticoid dosing should be individualized and the minimum effective dose/duration should be used. For select indications with weight-based dosing, consider using ideal body weight in obese patients, especially with longer durations of therapy (Erstad 2004; Furst 2019a). Hypothalamic-pituitary-adrenal suppression: Although some patients may become hypothalamic-pituitary-adrenal (HPA) suppressed with lower doses or briefer exposure, some experts consider HPA-axis suppression likely in any adult receiving >16 mg/day (daytime dosing) or ≥4 mg per 24 hours (evening or night dosing) for >3 weeks, or with Cushingoid appearance (Furst 2019b; Joseph 2016); do not abruptly discontinue treatment in these patients; dose tapering may be necessary (Cooper 2003). Safety: Only the methylprednisolone succinate formulation (Solu-Medrol) may be given IV. Methylprednisolone acetate suspension (Depo-Medrol) is intended for IM or intra-articular administration only; do not administer the acetate preparation IV (Grissinger 2007; ISMP 2016).

Usual dosage range:

IV (succinate): 40 to 125 mg/day given in a single daily dose or in divided doses; rarely, for certain conditions, may go up to 1 to 2 mg/kg/day.

Initial high-dose “pulse” therapy for select indications (eg, severe systemic rheumatic disorders): 7 to 15 mg/kg/dose (or 500 mg to 1 g/dose) given once daily for 3 to 5 days.

Oral: 16 to 64 mg/day once daily or in divided doses.

The following dosing is from the commercially available tapered-dosage product (eg, dose-pack containing 21 × 4 mg tablets):

Day 1: 24 mg on day 1 administered as 8 mg (2 tablets) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime or 24 mg (6 tablets) as a single dose or divided into 2 or 3 doses upon initiation (regardless of time of day).

Day 2: 20 mg on day 2 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime.

Day 3: 16 mg on day 3 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 4 mg (1 tablet) at bedtime.

Day 4: 12 mg on day 4 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, and 4 mg (1 tablet) at bedtime.

Day 5: 8 mg on day 5 administered as 4 mg (1 tablet) before breakfast and 4 mg (1 tablet) at bedtime.

Day 6: 4 mg on day 6 administered as 4 mg (1 tablet) before breakfast.

IM (acetate or succinate): 40 to 60 mg as a single dose.

Intra-articular (acetate suspension): Note: Dose ranges per manufacturer's labeling. Specific dose is determined based upon joint size, severity of inflammation, amount of articular fluid present, and clinician judgment.

Larger joint (eg, knee, shoulder, hip): 20 to 80 mg.

Medium joint (eg, wrist, ankle, elbow): 10 to 40 mg.

Small joint (eg, toe, finger): 4 to 10 mg.

Intralesional (acetate) (alternative agent): Note: Other agents (eg, triamcinolone acetonide) may be more commonly employed (Mathes 2020).

Usual dosage range: 20 to 60 mg; for large lesions, it may be necessary to distribute doses ranging from 20 to 40 mg by repeated local injections; 1 to 4 injections are usually employed with intervals between injections varying with the type of lesion being treated and clinical response.

Acute respiratory distress syndrome, moderate to severe

Acute respiratory distress syndrome, moderate to severe (off-label use): Note: May consider in most patients with persistent or refractory, moderate to severe acute respiratory distress syndrome, who are relatively early in the disease course (within 14 days) (Siegel 2020). Use ideal body weight to calculate dose. If patient is extubated between days 1 to 14, advance to day 15 of therapy and taper according to the following schedule. Do not abruptly discontinue since this may cause deterioration due to inflammatory response (Meduri 2007; SCCM/ESICM [Annane 2017]; Steinberg 2006).

IV (succinate): Loading dose of 1 mg/kg over 30 minutes, followed by a gradual taper:

Days 1 to 14: 1 mg/kg/day in divided doses or as a continuous infusion.

Days 15 to 21: 0.5 mg/kg/day in divided doses or as a continuous infusion.

Days 22 to 25: 0.25 mg/kg/day in divided doses or as a continuous infusion.

Days 26 to 28: 0.125 mg/kg/day in divided doses or as a continuous infusion.

Allergic conditions

Allergic conditions:

Anaphylaxis (adjunct to epinephrine for prevention of late-phase/biphasic reaction): Note: Do not use for initial or sole treatment of anaphylaxis because corticosteroids do not result in the prompt relief of upper or lower airway obstruction or shock (AAAAI [Lieberman 2015]; EAACI [Muraro 2014]; WAO [Simons 2011]; WAO [Simons 2015]). Some experts limit use to patients with severe or persistent steroid-responsive symptoms (eg, bronchospasm in patients with asthma) (Campbell 2021).

IV (succinate): 1 to 2 mg/kg (Campbell 2014) or 40 to 125 mg as a single dose (Campbell 2021; Castells 2021; WAO [Simons 2011]).

Angioedema (acute allergic) and/or new-onset urticaria: Note: For moderate to severe symptoms without signs of anaphylaxis. Use epinephrine if anaphylaxis symptoms (eg, risk of airway or cardiovascular compromise) are present (Cicardi 2014; Zuraw 2021). In patients with new-onset urticaria, reserve use for those with significant angioedema or with symptoms that are unresponsive to antihistamines (AAAAI/ACAAI [Bernstein 2014]; Asero 2021; EAACI [Zuberbier 2018]). The optimal dosing strategy has not been defined (AAAAI/ACAAI [Bernstein 2014]; EAACI [Zuberbier 2018]).

IV (succinate): Initial: 60 to 80 mg; switch to an oral corticosteroid as soon as possible, tapering the dose for a total treatment duration of ≤10 days (EAACI [Zuberbier 2018]; Zuraw 2021).

Oral: Note: Dose is based on prednisone equivalency. An example regimen is 16 to 48 mg daily initially, followed by a taper over 5 to 7 days (Asero 2021; EAACI [Zuberbier 2018]; Zuraw 2021). The total treatment duration should not exceed 10 days (EAACI [Zuberbier 2018]).

Asthma, acute exacerbation

Asthma, acute exacerbation: Note: For moderate to severe exacerbations or in patients who do not respond promptly and completely to short-acting beta agonists; administer within 1 hour of presentation to emergency department (GINA 2021).

Oral , IV (succinate): 40 to 60 mg/day in 1 or 2 divided doses for 5 to 7 days (GINA 2021; NAEPP 2007); doses up to 60 to 80 mg every 6 to 12 hours have been used in critically ill patients (Fanta 2019). If symptoms do not resolve and peak expiratory flow is not at least 70% of personal best, then longer treatment may be required (NAEPP 2007).

Chronic obstructive pulmonary disease, acute exacerbation

Chronic obstructive pulmonary disease, acute exacerbation (off-label use): Note: In patients with severe but not life-threatening exacerbations, oral regimens are recommended. Use IV route in patients who cannot tolerate oral therapy (eg, shock, mechanically ventilated) (GOLD 2020; Stoller 2019).

Oral; IV (succinate): 40 to 60 mg daily for 5 to 14 days (GOLD 2020; Stoller 2019). Doses up to 60 mg every 6 hours have been used in critically ill patients, although outcome data are limited. Note: Dose is based on an equivalent dose of prednisone; optimal dose has not been established. If patient improves with therapy, may discontinue without taper. If patient does not improve, a longer duration of therapy may be indicated (Stoller 2019).

COVID-19, hospitalized patients

COVID-19, hospitalized patients (severe or critical) (alternative agent) (off-label use):

Note: Methylprednisolone is recommended for treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support when dexamethasone is not available or there are specific indications for methylprednisolone. Corticosteroid dosing is extrapolated from a study that used dexamethasone; the equivalent dose of methylprednisolone (or other glucocorticoid) may be substituted when dexamethasone is unavailable (IDSA [Bhimraj 2022]; NIH 2022b; WHO 2020).

Oral; IV (succinate): 32 mg once daily or 16 mg twice daily for up to 10 days (or until discharge, if sooner) as part of an appropriate combination regimen (IDSA [Bhimraj 2022]; NIH 2022b; WHO 2020).

Deceased organ donor management

Deceased organ donor management (hormonal resuscitation for the deceased organ donor) (off-label use): Note: Data supporting benefit are conflicting; if given, it should be administered after blood has been collected for tissue typing (Dupuis 2014; SCCM/ACCP/AOPO [Kotloff 2015]).

IV (succinate): Regimens include: 1 g (as an IV infusion) or 15 mg/kg (as an IV infusion) or 250 mg (as an IV bolus) followed by a continuous infusion at 100 mg/hour; usually given as part of combination hormone therapy (SCCM/ACCP/AOPO [Kotloff 2015]).

Giant cell arteritis, treatment

Giant cell arteritis, treatment: Note: Due to the rapidly progressive nature of the disease, start treatment immediately once diagnosis is highly suspected (Dasgupta 2010). In patients presenting without threatened/evolving vision loss, an oral glucocorticoid is suggested as initial therapy rather than IV methylprednisolone (Docken 2019).

Initial pulse therapy in patients presenting with threatened/evolving vision loss: IV (succinate): 500 mg to 1 g daily for 3 days, followed by an oral glucocorticoid (eg, prednisone) (Dasgupta 2010).

Gout, treatment

Gout, treatment (acute flares):

Note: Avoid use in patients with known or suspected septic arthritis (Gaffo 2022).

Intra-articular (acetate): Note: Consider in patients with gout flare limited to 1 or 2 affected joints; clinicians must have sufficient expertise to perform arthrocentesis and injection (ACR [FitzGerald 2020]; Gaffo 2022). May mix with an equal volume of local anesthetic (Cardone 2002; Roberts 2021). Dose is individualized based on joint size, disease severity, and clinician judgment (Gaffo 2022). Typical doses are:

Large joint (eg, knee): 40 mg as a single dose (Gaffo 2022; manufacturer's labeling).

Medium joint (eg, wrist, ankle, elbow): 30 mg as a single dose (Gaffo 2022; manufacturer's labeling).

Small joint (eg, toe, finger): 10 mg as a single dose (Gaffo 2022; manufacturer's labeling).

Oral: Note: Some experts reserve use for patients who are not candidates for intra-articular glucocorticoids or when intra-articular glucocorticoid administration is not feasible (Gaffo 2022).

24 to 32 mg/day given once daily or in 2 divided doses until symptom improvement (usually 2 to 5 days), then taper gradually as tolerated (typically over 7 to 10 days); a slower taper (eg, over 14 to 21 days) may be required, particularly in patients with multiple recent flares (ACP [Qaseem 2017]; ACR [Khanna 2012]; EULAR [Richette 2017]; Gaffo 2022).

IM (acetate or succinate) (alternative route): Note: Reserve for patients who are not candidates for oral therapies or intra-articular glucocorticoid administration.

Initial: 40 to 60 mg as a single dose; may repeat once or twice at ≥48-hour intervals if benefit fades or there is no flare resolution (Gaffo 2022).

IV (succinate) (alternative route): Note: Reserve for hospitalized patients who are not candidates for oral therapies or intra-articular glucocorticoid administration.

Initial: 20 mg twice daily until clinical improvement (usually 2 to 5 days), then reduce each dose by 50% until tapered; transition to an equivalent dose of an oral glucocorticoid (eg, prednisone) as soon as possible to complete taper (ACR [Khanna 2012]; Gaffo 2022).

Graft-versus-host disease, acute, treatment

Graft-vs-host disease, acute, treatment (off-label use): Note: For grade ≥2 acute graft-versus-host disease. An optimal regimen has not been identified; refer to institutional protocols as variations exist. Treatment is dependent on the severity and the rate of progression (ASBMT [Martin 2012]; EBMT/ELN [Ruutu 2014]).

IV (succinate): Initial: 2 mg/kg/day in 2 divided doses; dose may vary based on organ involvement and severity. Continue for several weeks, then taper over several months (ASBMT [Martin 2012]; Zeiser 2022; EBMT/ELN [Ruutu 2014]).

Immune thrombocytopenia

Immune thrombocytopenia (initial therapy): Note: Goal of therapy is to provide a safe platelet count to prevent clinically important bleeding rather than normalization of the platelet count (Arnold 2022).

Patients with severe bleeding (in combination with other treatments): IV (succinate): 1 g once daily for 3 doses and then stop (no taper) (Arnold 2022; von dem Borne 1988). Note: Due to the short-term response, maintenance therapy with an oral glucocorticoid (eg, prednisone) may be required (Provan 2019).

Inflammatory bowel disease

Inflammatory bowel disease:

Crohn disease, acute (eg, severe/fulminant disease and/or unable to take oral) (adjunctive agent): Note: Not for long-term use (ACG [Lichtenstein 2018]). In patients with localized peritonitis, some experts recommend against initiating corticosteroids due to the potential of masking further clinical deterioration; however, if already receiving corticosteroids, continued use may be appropriate (Hashash 2021).

IV (succinate): 40 to 60 mg/day (ACG [Lichtenstein 2018]).

Note: For patients who have been receiving chronic treatment with a corticosteroid, a small increase in their daily dose may be required during an acute exacerbation (Hashash 2021). Steroid-sparing agents (eg, biologic agents, immunomodulators) should be introduced with a goal of discontinuing corticosteroid therapy as soon as possible (ACG [Lichtenstein 2018]).

Ulcerative colitis, acute (severe or fulminant): Note: Not for long-term use.

IV (succinate): 40 to 60 mg/day in 1 to 3 divided doses. If response to treatment is inadequate after 5 days (severe) or 3 days (fulminant), second-line therapy is initiated (ACG [Rubin 2019]; AGA [Feuerstein 2020]; Peppercorn 2019).

Iodinated contrast media allergic-like reaction, prevention

Iodinated contrast media allergic-like reaction, prevention: Note: Generally reserved for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent. Nonurgent premedication with an oral corticosteroid is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, consider an urgent (accelerated) regimen with an IV corticosteroid for those requiring contrast in <12 hours. Efficacy of premedication regimens starting <4 to 5 hours before the use of contrast has not been demonstrated (ACR 2021).

Nonurgent regimen:

Oral: 32 mg administered 12 hours and 2 hours before contrast medium administration in combination with oral or IV diphenhydramine (ACR 2021; Davenport 2021).

Urgent (accelerated) regimen:

IV (succinate): 40 mg every 4 hours until contrast medium administration in combination with IV diphenhydramine (ACR 2021). Some experts administer methylprednisolone 40 mg at 5 hours and 1 hour before contrast medium administration in combination with diphenhydramine (Davenport 2021).

Multiple sclerosis, acute exacerbation

Multiple sclerosis, acute exacerbation: Note: For patients with an acute exacerbation resulting in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function (Olek 2021).

Initial pulse therapy: IV (succinate): 500 mg to 1 g daily for 3 to 7 days (5 days typically), either alone or followed by an oral taper with prednisone (Goodin 2014; Le Page 2015; Myhr 2009; NICE 2014; Olek 2021).

Myopathies, treatment

Myopathies (dermatomyositis/polymyositis), treatment:

Initial pulse therapy in patients presenting with severe systemic involvement or profound weakness: IV (succinate): 1 g daily for 3 to 5 days, followed by oral prednisone (Dalakas 2011; Findlay 2015).

Nausea and vomiting of pregnancy, severe/refractory

Nausea and vomiting of pregnancy, severe/refractory (off-label use): Note: Reserve use as an add-on therapy when all other pharmacologic regimens have failed.

IV (succinate): 16 mg every 8 hours for 3 days. If no response within 3 days, discontinue treatment. If symptoms improve, complete 3-day course of treatment, then taper dose over 2 weeks (ACOG 189 2018; Safari 1998).

Pneumocystis pneumonia, adjunctive therapy for moderate to severe disease

Pneumocystis pneumonia, adjunctive therapy for moderate to severe disease (off-label use): Note: Recommended when on room air PaO2 <70 mm Hg or PAO2-PaO2 ≥35 mm Hg. Dosing is based on an equivalent dose of prednisone.

IV (succinate): 30 mg twice daily on days 1 to 5 beginning as early as possible, followed by 30 mg once daily on days 6 to 10, then 15 mg once daily on days 11 to 21 (AST [Martin 2013]; HHS [OI adult 2019]; Sax 2020; Thomas 2019).

Prostate cancer, metastatic, castration resistant

Prostate cancer, metastatic, castration-resistant (off-label use): Oral: 4 mg twice daily (in combination with micronized abiraterone acetate) (Stein 2018).

Sarcoidosis, severe, acute

Sarcoidosis, severe, acute (off-label use):

Note: For use in patients with life-threatening extrapulmonary disease manifestations (eg, ventricular arrhythmias, transverse myelitis) or rapidly progressive disease (eg, severe optic neuritis) (Bradshaw 2021; BTS [Thillai 2021]; Lui 2022; Melani 2021; Perlman 2021).

Fixed dose: IV (succinate): 500 mg/day to 1 g per day for 3 to 5 days, followed by an oral glucocorticoid (eg, prednisone) (Bradshaw 2021; Chapelon-Abric 2017; Durel 2016; Lui 2022; Melani 2021; Perlman 2021).

Weight-based dosing : IV (succinate): 10 to 20 mg/kg/day for 3 days, followed by an oral glucocorticoid (eg, prednisone) (Chapelon-Abric 2004; Stern 2004).

Systemic rheumatic disorders, organ-threatening or life-threatening

Systemic rheumatic disorders (eg, antineutrophil cytoplasmic antibody-associated vasculitis, mixed cryoglobulinemia syndrome, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus), organ-threatening or life-threatening: Note: The following dosage ranges are for guidance only; dosing should be highly individualized, taking into account disease severity, the specific disorder, and disease manifestations.

Initial pulse therapy (optional): IV (succinate): 7 to 15 mg/kg/day (maximum dose: 500 mg to 1 g/day) typically for up to 3 days, followed by an oral glucocorticoid (eg, prednisone); may be given as part of an appropriate combination regimen. Lower doses (eg, 250 mg/day) may be appropriate in some patients (eg, less severe manifestations) (Fervenza 2020; Forbess 2015; Merkel 2020; Muchtar 2017).

Warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia:

IV (succinate): 250 mg to 1 g daily for 1 to 3 days, followed by an oral glucocorticoid (eg, prednisone) (Barros 2010; Zanella 2014); a clinician experienced with the treatment of hemolytic anemia should be involved with therapy.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: The pharmacokinetics and pharmacodynamics of methylprednisolone in kidney impairment are not well understood (Czock 2005; Honoré 2014). Methylprednisolone clearance appears unaltered in patients with uremia (Czock 2005; Milad 1994) and it is slightly dialyzable (Czock 2005; Sherlock 1977).

Altered kidney function: No dosage adjustment necessary for any degree of kidney impairment (expert opinion).

Hemodialysis, intermittent (thrice weekly): No supplemental dose or dosage adjustment necessary (expert opinion).

Peritoneal dialysis: No dosage adjustment necessary (expert opinion).

CRRT: No dosage adjustment necessary (expert opinion).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (expert opinion).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Pediatric

(For additional information see "Methylprednisolone: Pediatric drug information")

Note: Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed. Only sodium succinate salt may be given IV.

General dosing; anti-inflammatory or immunosuppressive (manufacturer's labeling):

Methylprednisolone sodium succinate (immediate acting): Infants, Children, and Adolescents: Oral, IV, IM: 0.11 to 1.6 mg/kg/day in 3 to 4 divided doses.

Methylprednisolone acetate (long acting): Infants, Children, and Adolescents:

IM: 0.11 to 1.6 mg/kg/dose; frequency depends upon condition being treated, usually administered as a one-time dose or every 1 to 2 weeks.

Intra-articular: Dosing varies based on affected joint; general range: 4 to 80 mg every 1 to 5 weeks.

Anaphylaxis, adjunctive therapy: Limited data available:

Note: Administer epinephrine first when treating anaphylaxis. Corticosteroids are considered second- or third-line therapy and do not result in prompt resolution of airway obstruction or shock. Use of corticosteroids for anaphylaxis is controversial; they have little to no benefit on initial symptoms; typically administered to prevent biphasic or prolonged episodes of anaphylaxis (AAAAI/ACAAI [Lieberman 2015]; AAAAI/ACAAI [Shaker 2020]; EAACI [Muraro 2014]; WAO [Cardona 2020]; WAO [Simons 2011]; WAO [Simons 2015]).

Infants, Children, and Adolescents: IV, IM (succinate): 1 to 2 mg/kg/dose as a single dose; maximum dose: 125 mg/dose (AAAAI/ACAAI [Lieberman 2015]; WAO [Simons 2011]).

Asthma:

Acute exacerbation:

Outpatient management (short-course "burst") (NAEPP 2007):

Oral: Note: Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required.

Infants and Children <12 years: Oral: 1 to 2 mg/kg/day in 1 or 2 divided doses for 3 to 10 days; maximum daily dose: 60 mg/day.

Children ≥12 years and Adolescents: Oral: 40 to 60 mg/day in 1 or 2 divided doses for 3 to 10 days.

IM (acetate): Note: This may be given in place of short-course "burst" of oral steroids in patients who are vomiting or if compliance is a problem.

Children ≤4 years: IM: 7.5 mg/kg as a one-time dose; maximum dose: 240 mg.

Children ≥5 years and Adolescents: IM: 240 mg as a one-time dose.

Emergency/acute care management:

Infants and Children <12 years: Oral, IV (succinate): 1 to 2 mg/kg/day in 2 divided doses; maximum daily dose: 60 mg/day; continue until peak expiratory flow is 70% of predicted or personal best (NAEPP 2007). Some experts suggest infants and children ≤5 years may receive IV doses of 1 mg/kg/dose every 6 hours on day 1, followed by transition to oral corticosteroids to complete a 3 to 5 days course (GINA 2021).

Children ≥12 years and Adolescents: Oral, IV (succinate): 40 to 80 mg/day in 1 or 2 divided doses until peak expiratory flow is 70% of predicted or personal best (NAEPP 2007).

Status asthmaticus: Children and Adolescents: IV (succinate): Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours (Carroll 2013; Giuliano 2013; Younger 1987).

Long-term treatment (non-acute), severe, persistent asthma (NAEPP 2007):

Infants and Children <12 years: Oral: 0.25 to 2 mg/kg/day once daily in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/day.

Children ≥12 years and Adolescents: Oral: 7.5 to 60 mg once daily in the morning or every other day as needed for asthma control.

Graft-versus-host disease, acute (GVHD): Limited data available: Infants, Children, and Adolescents: IV (succinate): 1 to 2 mg/kg/dose once daily; if using low dose (1 mg/kg) and no improvement after 3 days, increase dose to 2 mg/kg. Continue therapy for 5 to 7 days; if improvement observed, may taper by 10% of starting dose every 4 days; if no improvement, then considered steroid-refractory GVHD and additional agents should be considered (Carpenter 2010).

Immune thrombocytopenia, moderate to severe bleeding or at risk for severe bleeding: Limited data available:

Infants, Children, and Adolescents: IV (succinate): Initial: Pulse: 30 mg/kg/dose once daily for 1 to 3 doses; number of doses is determined by patient clinical status, initial and postdose platelet counts, and if used in conjunction with other therapies; maximum dose: 1,000 mg/dose; follow with oral corticosteroid therapy as clinically indicated (Ancona 2002; Gereige 2000; Provan 2019).

Juvenile idiopathic arthritis, systemic: Note: Therapy should be individualized based on disease severity and activity (CARRA [Dewitt 2012]). Limited data available:

Children and Adolescents: IV (succinate): Pulse therapy: 30 mg/kg/day once daily for 3 days; maximum dose: 1,000 mg/dose. Follow pulse therapy with oral corticosteroids; evaluate initial response at 1 to 2 weeks and then at 1 month of therapy; if condition worsens or unchanged at either time interval, may repeat methylprednisolone 30 mg/kg/dose at weekly intervals as clinically indicated (CARRA [DeWitt 2012]).

Kawasaki disease: Limited data available; optimal regimen not established; efficacy variable:

Primary treatment, patients at high risk for coronary artery aneurysms:

Pulse dosing: Infants and Children: IV (succinate): 30 mg/kg/dose as a single dose in combination with intravenous immune globulin (IVIG) and aspirin (AHA [McCrindle 2017]; Ogata 2012; Okada 2009).

Taper dosing: Infants and Children: IV (succinate): 1.6 mg/kg/day in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/day; give in combination with aspirin and an additional dose of IVIG (AHA [McCrindle 2017]; Kobayashi 2012). Note: Dosing based on use of IV prednisolone product (2 mg/kg/day) which is not available in the United States; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.

Treatment, refractory/resistant disease: Note: Reserve use for patients who remain febrile after initial IVIG dose:

Pulse dosing: Infants and Children: IV (succinate): 30 mg/kg/dose once daily for 1 or 3 days; may be given in combination with additional IVIG dose (AHA [McCrindle 2017]; Ebato 2017; Miura 2008).

Taper dosing: Infants and Children: IV (succinate): 1.6 mg/kg/day in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/day; give in combination with aspirin and an additional dose of IVIG (AHA [McCrindle 2017]; Kobayashi 2012; Kobayashi 2013). Note: Dosing based on use of IV prednisolone product (2 mg/kg/day) which is not available in the United States; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.

Lupus nephritis, proliferative (induction): Limited data available: Children and Adolescents: IV (succinate): Initial pulse therapy: 30 mg/kg/dose once daily for 3 doses; maximum dose: 1,000 mg/dose (CARRA [Mina 2012]; Chalhoub 2021; EULAR/ERA-EDTA [Fanouriakis 2020]; SHARE [Groot 2017]). Reported dosage range: 10 to 30 mg/kg/dose or 500 to 1,000 mg/m2/dose once daily for 3 days. Following pulse therapy transition to oral corticosteroids and taper as clinically indicated. May be given as part of an appropriate combination dosage regimen (Adams 2006; Aragon 2010; Basu 2017; Chalhoub 2021; Hogan 2018; Marks 2010).

Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: Limited data available:

Infants, Children, and Adolescents:

Initial therapy: IV (succinate): 1 to 2 mg/kg/day divided twice daily in combination with IVIG; duration is dependent on clinical course; may then transition to oral steroids, with taper over at least 2 to 3 weeks (ACR [Henderson 2022]; Cattalini 2021; Clouser 2020; Jonat 2021; Ouldali 2021; NIH 2022a; Son 2021). Note: High-dose corticosteroid therapy at doses of 10 to 30 mg/kg/day (maximum dose: 1,000 mg/dose) for 1 to 3 days has also been reported as initial therapy of MIS-C in patients with more severe disease (eg, shock symptoms) (AAP 2021; Cattalini 2021; Chiotos 2020; Clouser 2020; Jonat 2021).

Intensification therapy (in patients who do not improve within 24 hours of initial MIS-C therapy with low- to moderate-dose corticosteroid therapy and IVIG): IV (succinate): 10 to 30 mg/kg/day (maximum dose: 1,000 mg/dose) for 1 to 3 days (ACR [Henderson 2022]; Cattalini 2021; Chiotos 2020; Clouser 2020; Gupta 2020; NIH 2022a; Son 2021).

Nephrotic syndrome, steroid resistant: Limited data available, variable regimens reported: Children and Adolescents: Pulse therapy: IV (succinate): 15 to 30 mg/kg/dose or 500 mg/m2/dose once daily for 3 days; maximum dose: 1,000 mg/dose. Transition to oral corticosteroid and taper as clinically indicated (IPNA [Trautman 2020]; KDIGO 2021; Shenoy 2010; Zhang 2016). Additional pulse doses may be required; some regimens include multiple pulses over a few months until remission (Bahat 2007; Hari 2004; Mori 2004; Peña 2007).

Pneumocystis pneumonia (PCP), adjunctive therapy for moderate or severe infection: Limited data available: Note: Recommended when on room air PaO2 <70 mm Hg or PAO2-PaO2 ≥35 mm Hg. Begin as soon as possible after diagnosis and within 72 hours of PCP therapy.

Infants and Children: IV (succinate): 1 mg/kg/dose every 6 hours on days 1 to 7, then 1 mg/kg/dose twice daily on days 8 to 9, then 0.5 mg/kg/dose twice daily on days 10 and 11, and 1 mg/kg/dose once daily on days 12 to 16 (HHS [OI pediatric 2021]).

Adolescents: IV (succinate): 30 mg twice daily on days 1 to 5, then 30 mg once daily on days 6 to 10, then 15 mg once daily on days 11 to 21 (HHS [OI adult 2021]).

Radiocontrast media reaction, prevention of rebound reaction: Limited data available: Note: If patient is experiencing anaphylaxis, administer epinephrine first. Corticosteroids may be utilized to prevent rebound reactions.

Infants, Children, and Adolescents: IV (succinate): 1 mg/kg/dose; maximum dose: 40 mg/dose (ACR 2021).

Ulcerative colitis, acute, severe: Limited data available: Children and Adolescents: IV (succinate): 1 to 1.5 mg/kg/day once daily or in divided doses 2 times daily; maximum daily dose: 60 mg/day. Higher doses should be reserved for patients with severe disease and/or who have failed oral steroids. Transition to oral therapy when clinically appropriate. If inadequate response after 3 to 5 days of IV therapy, initiate second-line therapy (ECCO/ESPGHAN [Turner 2018]).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. The pharmacokinetic and pharmacodynamic properties of methylprednisolone in kidney impairment are not well understood (Czock 2005; Honoré 2014). Methylprednisolone clearance appears unaltered in patients with uremia (Czock 2005; Milad 1994) and it is slightly dialyzable (Czock 2005; Sherlock 1977).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Injection, as acetate:

P-Care D40: 40 mg/mL [DSC] [contains polyethylene glycol (macrogol)]

P-Care D80: 40 mg/mL [DSC] [contains polyethylene glycol (macrogol)]

Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]:

SOLU-Medrol: 500 mg (1 ea)

SOLU-Medrol: 2 g (1 ea [DSC]) [contains benzyl alcohol]

Generic: 40 mg (1 ea); 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)

Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]:

SOLU-Medrol: 40 mg (1 ea) [contains lactose]

SOLU-Medrol: 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea); 2 g (1 ea)

Suspension, Injection, as acetate:

DEPO-Medrol: 20 mg/mL (5 mL); 40 mg/mL (5 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol (macrogol), polysorbate 80]

DEPO-Medrol: 40 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]

DEPO-Medrol: 80 mg/mL (5 mL) [contains benzyl alcohol, polyethylene glycol (macrogol), polysorbate 80]

DEPO-Medrol: 80 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]

Generic: 40 mg/mL (1 mL, 5 mL, 10 mL); 80 mg/mL (1 mL, 5 mL)

Suspension, Injection, as acetate [preservative free]:

DEPO-Medrol: 40 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]

Generic: 40 mg/mL (1 mL); 80 mg/mL (1 mL)

Tablet, Oral:

Medrol: 2 mg, 8 mg, 16 mg, 32 mg, 4 mg [scored]

Generic: 8 mg, 16 mg, 32 mg, 4 mg

Tablet Therapy Pack, Oral:

Medrol: 4 mg (21 ea) [scored]

Generic: 4 mg (21 ea)

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]:

SOLU-medrol: 40 mg (1 ea) [contains benzyl alcohol, lactose]

Solu-MEDROL: 125 mg (1 ea) [contains benzyl alcohol]

Solu-MEDROL: 500 mg (1 ea)

Solu-MEDROL: 500 mg (1 ea) [contains benzyl alcohol]

Solu-MEDROL: 1000 mg (1 ea)

Generic: 40 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)

Suspension, Injection, as acetate:

Depo-Medrol: 20 mg/mL (5 mL) [contains benzyl alcohol]

Depo-Medrol: 40 mg/mL (1 mL)

Depo-Medrol: 40 mg/mL (2 mL, 5 mL) [contains benzyl alcohol]

Depo-Medrol: 80 mg/mL (1 mL)

Depo-Medrol: 80 mg/mL (5 mL) [contains benzyl alcohol]

Generic: 40 mg/mL ([DSC]); 80 mg/mL ([DSC])

Tablet, Oral:

Medrol: 16 mg, 4 mg

Administration: Adult

Oral: Administer tablets after meals or with food or milk to decrease GI upset. If prescribed once daily, administer in the morning.

IM (acetate, succinate): Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis. Do not inject into areas that have evidence of acute local infection.

IV (succinate):

IV push: May administer as a slow IV injection. Recommended rates range from over several minutes (dose not specified; US manufacturer's labeling) to over at least 5 minutes for doses ≤250 mg (Canadian manufacturer's labeling). Also refer to institution-specific policies and procedures.

Intermittent IV infusion: Rate dependent upon dose and severity of condition; typically administered as an intermittent infusion over 15 to 60 minutes. Administer doses >250 mg over at least 30 to 60 minutes; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving methylprednisolone doses ≥250 mg administered over <30 minutes (Ditzian-Kadanoff 1987; Erstad 1989; Guillén 1998; Lucas 1993). Also refer to institution-specific policies and procedures. Note: In some spinal cord injury trials, bolus doses (30 mg/kg) have been administered over 15 minutes. Do not administer acetate form IV.

Intra-articular or soft tissue (acetate): See manufacturer's labeling for details.

Intralesional: Inject directly into the lesion. For large lesions, administer multiple small injections (20 to 40 mg) into the area of the lesion. Avoid injection of sufficient material to cause blanching because this may be followed by a small slough.

Administration: Pediatric

Oral: Administer after meals or with food or milk to decrease GI upset. If prescribed once daily, administer dose in the early morning to mimic the normal diurnal variation of endogenous cortisol.

Parenteral:

IM: Acetate, succinate: Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis. Do not inject into areas that have evidence of acute local infection. Discard contents of single-dose vial after use.

IV: Succinate:

IV push: May administer as a slow IV injection. Recommended rates range from over several minutes (dose not specified; US manufacturer's labeling) to over at least 5 minutes for doses ≤250 mg (Canadian manufacturer's labeling). Also refer to institution-specific policies and procedures.

Intermittent IV infusion: Rate dependent upon dose and severity of condition; typically administered as an intermittent infusion over 15 to 60 minutes. Administer doses >250 mg over at least 30 to 60 minutes; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving methylprednisolone doses ≥250 mg administered over <30 minutes (Ditzian-Kadanoff 1987; Erstad 1989; Guillén 1998; Lucas 1993). Pulse doses of 15 to 30 mg/kg used in rheumatic or kidney diseases in pediatric patients have been infused over 1 to 4 hours (Hari 2004; Mori 2004; Peña 2007; Shenoy 2010; Zhang 2016). Also refer to institution-specific policies and procedures. Do not administer acetate form IV.

Use: Labeled Indications

Oral, IM (acetate or succinate), and IV (succinate only) administration: Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of hematologic (eg, immune thrombocytopenia, warm autoimmune hemolytic anemia), allergic (eg, asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis [oral only], serum sickness, transfusion reactions, new-onset urticaria), GI (eg, Crohn disease, ulcerative colitis), inflammatory, neoplastic, neurologic (eg, multiple sclerosis), rheumatic (eg, antineutrophil cytoplasmic antibody-associated vasculitis, dermatomyositis/polymyositis, giant-cell arteritis, gout [acute flare], giant cell arteritis, mixed cryoglobulinemia syndrome, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus), and/or autoimmune origin.

Intra-articular or soft tissue administration (acetate only): Gout (acute flare), acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and/or synovitis of osteoarthritis.

Intralesional administration (acetate only): Alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; and necrobiosis lipoidica diabeticorum. May be useful in cystic tumor of an aponeurosis or tendon (ganglia).

Use: Off-Label: Adult

Acute respiratory distress syndrome, moderate to severe; Cardiac transplant: Acute cellular rejection (treatment); Cardiac transplant: Antibody-mediated rejection (treatment); Chronic obstructive pulmonary disease (acute exacerbation); COVID-19, hospitalized patients (severe or critical); Deceased organ donor management (hormonal resuscitation for the deceased organ donor); Graft-vs-host disease, acute; Nausea and vomiting of pregnancy, severe/refractory; Pneumocystis pneumonia, adjunctive therapy for moderate to severe disease; Prostate cancer, metastatic, castration-resistant; Sarcoidosis, severe, acute

Medication Safety Issues
Sound-alike/look-alike issues:

MethylPREDNISolone may be confused with medroxyPROGESTERone, methotrexate, methylTESTOSTERone, predniSONE

DEPO-Medrol may be confused with Depo-Provera, SOLU-Medrol

Medrol may be confused with Mebaral

SOLU-Medrol may be confused with salmeterol, Solu-CORTEF

International issues:

Medrol [US, Canada, and multiple international markets] may be confused with Medral brand name for omeprazole [Mexico]

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmia, cardiac failure, cardiomegaly, circulatory shock, edema, embolism (fat), hypertension, hypertrophic cardiomyopathy (in neonates), myocardial rupture (post MI), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis

Central nervous system: Arachnoiditis, depression, emotional lability, euphoria, headache, increased intracranial pressure, insomnia, malaise, meningitis, myasthenia, neuritis, neuropathy, paraplegia, paresthesia, personality changes, psychic disorders, pseudotumor cerebri (usually following discontinuation), seizure, sensory disturbance, vertigo

Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, diaphoresis, ecchymoses, epidermal thinning, erythema, exfoliation of skin, facial erythema, hyperpigmentation, hypertrichosis, hypopigmentation, skin atrophy, skin rash, suppression of skin test reaction, thinning hair, urticaria, xeroderma

Endocrine & metabolic: Adrenal suppression, calcinosis, cushingoid state, Cushing syndrome, decreased glucose tolerance, diabetes mellitus, fluid retention, glycosuria, growth suppression (children), hirsutism, HPA-axis suppression, hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, insulin resistance (increased requirements for insulin or oral hypoglycemic agents in diabetes), menstrual disease, moon face, negative nitrogen balance, protein catabolism, sodium retention, weight gain

Gastrointestinal: Abdominal distention, bladder dysfunction (after intrathecal administration, including bowel dysfunction), carbohydrate intolerance (increased), gastrointestinal hemorrhage, gastrointestinal perforation, hiccups, increased appetite, intestinal perforation (of both of the small and large intestines; especially in patients with inflammatory bowel disease), nausea, pancreatitis, peptic ulcer, spermatozoa disorder (decreased motility and number of spermatozoa), ulcerative esophagitis

Hematologic: Leukocytosis (transient), malignant neoplasm (secondary), petechia

Hepatic: Hepatomegaly, increased liver enzymes, increased serum transaminases

Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reaction

Infection: Increased susceptibility to infection, infection (ophthalmic), sterile abscess

Local: Injection site infection

Neuromuscular & skeletal: Amyotrophy, arthropathy, aseptic necrosis of femoral head, aseptic necrosis of humoral head, bone fracture, Charcot-like arthropathy, lipotrophy, osteoporosis, rupture of tendon, steroid myopathy, vertebral compression fracture

Ophthalmic: Blindness, exophthalmoses, glaucoma, increased intraocular pressure, ophthalmic inflammation (ophthalmic), subcapsular posterior cataract, visual impairment

Respiratory: Pulmonary edema, rhinitis

Miscellaneous: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reactions, tissue sloughing (residue or slough at injection site), wound healing impairment

<1%, postmarketing, and/or case reports: Venous thrombosis (Johannesdottir 2013)

Contraindications

Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection (except intra-articular injection for localized joint conditions); intrathecal administration; live or attenuated virus vaccines (with immunosuppressive doses of corticosteroids); use in premature infants (formulations containing benzyl alcohol preservative only); immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (IM administration only)

Additional contraindication: Methylprednisolone sodium succinate 40 mg vial only: Hypersensitivity to cow's milk or its components or other dairy products which may contain trace amounts of milk ingredients (known or suspected).

Canadian labeling: Additional contraindications (not in US labeling):

Methylprednisolone tablets: Herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)

Methylprednisolone acetate injection: Epidural or intravascular administration; intra-articular injections in unstable joints; herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)

Methylprednisolone sodium succinate: Epidural administration; herpes simplex keratitis, vaccinia and varicella, arrested tuberculosis, acute psychoses, Cushing syndrome, peptic ulcer, markedly elevated serum creatinine (except for short-term or emergency therapy)

Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving >20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections.

• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.

• Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur.

• Hepatic effects: High doses of methylprednisolone IV (usually doses of 1 g/day in adults) may induce a toxic form of acute hepatitis (rare); serious hepatic injury may occur, resulting in acute liver failure and death. Time to onset can be several weeks or longer; resolution has been observed after discontinuation of therapy. Discontinue methylprednisolone if toxic hepatitis occurs. Avoid use of high doses in patients with a history of methylprednisone-induced toxic hepatitis.

• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, cause activation of latent infections, mask acute infection (including fungal infections), prolong or exacerbate viral or parasitic infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination and fatalities have occurred.

• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); discontinuation may result in clinical improvement (Goedert 2002).

• Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.

• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression, or psychotic manifestations. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.

• Septic arthritis: May occur as a complication to parenteral therapy; institute appropriate antimicrobial therapy as required.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with heart failure (HF) and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute myocardial infarction (MI); corticosteroids have been associated with myocardial rupture.

• Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.

• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.

• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.

• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.

• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).

• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.

• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.

• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.

• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.

• Septic shock or sepsis syndrome: Corticosteroids should not be administered for the treatment of sepsis in the absence of shock (SCCM/ESICM [Annane 2017]). A study has failed to demonstrate efficacy in septic shock or sepsis syndrome treatment; use may increase mortality in some populations (eg, patients with elevated serum creatinine, patients who develop secondary infections after use).

• Systemic sclerosis (scleroderma): Use of higher dose corticosteroid therapy (in adults, ≥15 mg/day of prednisone or equivalent) in patients with systemic sclerosis may increase the risk of scleroderma renal crisis; avoid use when possible (Steen 1998; Trang 2012).

• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.

Special populations:

• Older adult: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.

• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Methylprednisolone acetate IM injection (multiple-dose vial) and the diluent for methylprednisolone sodium succinate injection may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997], CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. Additionally, benzyl alcohol may also be toxic to neural tissue when administered locally (eg, intra-articular, intralesional). See manufacturer's labeling.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.

• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.

• Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).

Warnings: Additional Pediatric Considerations

May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with >4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). Increased intraocular pressure (IOP) may occur, especially with prolonged use; in children, increased IOP has been shown to be dose dependent and produce a greater IOP in children <6 years of age than older children treated with ophthalmic dexamethasone (Lam 2005). Hypertrophic cardiomyopathy has been reported in premature neonates.

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib. Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive. Risk D: Consider therapy modification

Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy

Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination

Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy

Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. Risk C: Monitor therapy

Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects. Risk D: Consider therapy modification

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Aprepitant: May increase the serum concentration of MethylPREDNISolone. Management: Decrease the oral methylprednisolone dose by 50%, and decrease the intravenous methylprednisolone dose by 25%, when combined with aprepitant. Risk D: Consider therapy modification

Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib. Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive. Risk D: Consider therapy modification

BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral). Risk C: Monitor therapy

Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). Risk C: Monitor therapy

CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy. Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity. Risk D: Consider therapy modification

Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing. Risk D: Consider therapy modification

Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy

Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. Risk C: Monitor therapy

COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA vaccine at least 28 days after the primary vaccine dose. Patients should also receive 2 booster doses of mRNA vaccine - one 2 months after the 2nd (additional) dose and another 4 months after the first booster dose. Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups based on the brand of mRNA vaccine received. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

CycloSPORINE (Systemic): May enhance the neuroexcitatory and/or seizure-potentiating effect of MethylPREDNISolone. MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of MethylPREDNISolone. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of MethylPREDNISolone. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of MethylPREDNISolone. Risk C: Monitor therapy

Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider therapy modification

Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment. Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation. Risk D: Consider therapy modification

Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Fosaprepitant: May increase the serum concentration of MethylPREDNISolone. Management: Decrease the oral methylprednisolone dose by 50%, and decrease the intravenous methylprednisolone dose by 25%, when combined with fosaprepitant. Risk D: Consider therapy modification

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. Risk C: Monitor therapy

Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). Risk C: Monitor therapy

Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Risk D: Consider therapy modification

Immune Checkpoint Inhibitors: Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors. Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended Risk D: Consider therapy modification

Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. Risk X: Avoid combination

Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy. Risk D: Consider therapy modification

Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids. Risk D: Consider therapy modification

Licorice: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown. Risk D: Consider therapy modification

Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination

MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment. Risk X: Avoid combination

Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments Risk D: Consider therapy modification

Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased. Risk C: Monitor therapy

Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Risk X: Avoid combination

Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. Risk C: Monitor therapy

Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If post-exposure rabies vaccination is required during immunosuppressant therapy, administer a 5th dose of vaccine and check for rabies antibodies. Risk D: Consider therapy modification

Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. Risk C: Monitor therapy

Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy

Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. Risk C: Monitor therapy

Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive. Risk D: Consider therapy modification

Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. Risk C: Monitor therapy

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Risk C: Monitor therapy

Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. Risk C: Monitor therapy

Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. Risk C: Monitor therapy

Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive. Risk D: Consider therapy modification

Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib. Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks. Risk D: Consider therapy modification

Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. Risk C: Monitor therapy

Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored. Risk D: Consider therapy modification

Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone > 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines prior to therapy whenever possible. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Corticosteroids do not decrease fertility in patients with inflammatory bowel disease (IBD) who wish to become pregnant; however, active IBD may decrease fertility; pregnancy should be planned after a 3- to 6-month remission (Mahadevan 2019).

Pregnancy Considerations

Methylprednisolone crosses the placenta (Anderson 1981). Some products contain benzyl alcohol, which may also cross the placenta.

Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; however, information is conflicting and may be influenced by maternal dose, duration/frequency of exposure, and indication for use. Additional data are needed to evaluate any potential risk of systemic corticosteroids and other adverse pregnancy outcomes (eg, gestational diabetes mellitus, low birth weight, preeclampsia, preterm birth) (ACOG 776 2019; Bandoli 2017; Skuladottir 2014). Hypoadrenalism may occur in newborns following maternal use of corticosteroids; monitor infants exposed to prolonged or high doses of methylprednisolone in utero (Homar 2008; Kurtoğlu 2011).

Methylprednisolone is a preferred oral corticosteroid for the treatment of maternal conditions during pregnancy because placental enzymes limit passage to the embryo (ACOG 776 2019).

When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids such as methylprednisolone are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]). Methylprednisolone may also be used to treat acute exacerbations of multiple sclerosis during pregnancy (Canibaño 2020; Dobson 2019).

Corticosteroids may be used as needed for disease flares in pregnant patients with inflammatory bowel disease; however, maintenance therapy should be avoided (Mahadevan 2019).

Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma (ERS/TSANZ [Middleton 2020]; GINA 2021).

Methylprednisolone may be considered for adjunctive treatment of severe nausea and vomiting in pregnant patients. Due to risks of adverse fetal events associated with first trimester exposure, use is reserved for refractory cases in women with dehydration (ACOG 189 2018).

High dose methylprednisolone may be used in the management of immune thrombocytopenia in pregnant patients refractory to oral corticosteroids; use in combination with other therapies is suggested (Provan 2019).

Systemic corticosteroids are used off label in the management of COVID-19 (NIH 2022b). Methylprednisolone was not the corticosteroid evaluated in the initial study and large numbers of pregnant patients were not included (Horby 2021). However, in patients who do not require corticosteroids for other indications, or in those who have already completed a course of corticosteroids to enhance fetal lung development, equivalent doses of methylprednisolone may be preferred for use in pregnant patients with severe or critical COVID-19 due to limited placental transfer and less fetal risk. A treatment algorithm is available for pregnant patients with severe or critical COVID-19; the algorithm differentiates recommendations based on the patient's requirement for corticosteroids for fetal lung maturation. Close glucose monitoring is recommended (Saad 2020). The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients (ACOG 2022). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.

The Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.

Breastfeeding Considerations

Methylprednisolone is present in breast milk (Boz 2018; Cooper 2015; Strijbos 2015; Zengin Karahan 2020).

Information related to the presence of methylprednisolone in breast milk is available from a study following maternal administration of methylprednisolone 1,000 mg IV infused over 2 hours. Using the highest milk concentration (5.55 mcg/mL), the estimated daily infant dose via breast milk was 0.8325 mg/kg/day, providing a relative infant dose (RID) of methylprednisolone of 2.8% to 5.6% compared to a weight-adjusted infant dose of 15 to 30 mg/kg/day. The maximum milk concentration occurred 1 hour after the maternal dose and methylprednisolone was below the limits of quantification 12 hours after the dose (Cooper 2015). In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000).

The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.

Corticosteroids are generally considered acceptable in patients who are breastfeeding when used in usual doses; however, monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating patient for rheumatic disorders, low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).

If there is concern about exposure to the infant, waiting 2 to 4 hours after administration of methylprednisolone IV decreases exposure via breast milk (recommendation based on methylprednisolone pulse dosing for multiple sclerosis) (Cooper 2015; Zengin Karahan 2020). In addition, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding (based on a study using prednisolone) (ACR [Sammaritano 2020]; Ost 1985).

Dietary Considerations

Take tablets with meals to decrease GI upset; need diet rich in pyridoxine, vitamin C, vitamin D, folate, calcium, phosphorus, and protein.

Monitoring Parameters

Blood pressure, blood glucose, electrolytes; weight; intraocular pressure (use >6 weeks); bone mineral density; growth and development in children; HPA axis suppression

Mechanism of Action

In a tissue-specific manner, corticosteroids regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Moreover cardiovascular, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced by corticosteroids. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.

Pharmacokinetics

Onset of action: IV (succinate): Within 1 hour; Intra-articular (acetate): 1 week

Duration: Intra-articular (acetate): 1 to 5 weeks

Absorption: Oral: Well absorbed (Czock 2005)

Bioavailability: Oral: 88% ± 23% (Czock 2005)

Distribution: Vd: IV (succinate): 24 L ± 6 L (Czock 2005)

Metabolism: Hepatic to metabolites (Czock 2005)

Half-life elimination:

Adolescents: IV: 1.9 ± 0.7 hours (age range: 12 to 20 years; Rouster-Stevens 2008)

Adults: Oral: 2.5 ± 1.2 hours (Czock 2005); IV (succinate): 0.25 ± 0.1 hour (Czock 2005)

Time to peak, plasma:

Oral: 2.1 ± 0.7 hours (Czock 2005)

IV (succinate): 0.8 hours (Czock 2005)

Excretion: Urine (1.3% [oral], 9.2% [IV succinate] as unchanged drug) (Czock 2005)

Pharmacokinetics: Additional Considerations

Older adult: Decreased clearance and increased half-life (Czock 2005)

Obesity: Decreased clearance and increased half-life (Czock 2005)

Pricing: US

Solution (reconstituted) (methylPREDNISolone Sodium Succ Injection)

40 mg (per each): $5.76 - $7.30

125 mg (per each): $9.12 - $13.98

500 mg (per each): $26.40 - $27.74

1000 mg (per each): $39.00 - $50.27

Solution (reconstituted) (SOLU-Medrol Injection)

2 g (per each): $113.10

40 mg (per each): $7.26

125 mg (per each): $11.69

500 mg (per each): $29.14

1000 mg (per each): $52.78

Suspension (DEPO-Medrol Injection)

20 mg/mL (per mL): $8.53

40 mg/mL (per mL): $13.63

80 mg/mL (per mL): $23.67

Suspension (methylPREDNISolone Acetate Injection)

40 mg/mL (per mL): $10.44 - $11.57

80 mg/mL (per mL): $17.16 - $19.58

Tablet Therapy Pack (Medrol Oral)

4 mg (per each): $0.37

Tablet Therapy Pack (methylPREDNISolone Oral)

4 mg (per each): $1.43 - $1.65

Tablets (Medrol Oral)

2 mg (per each): $1.97

4 mg (per each): $0.37

8 mg (per each): $2.14

16 mg (per each): $3.45

32 mg (per each): $12.04

Tablets (methylPREDNISolone Oral)

4 mg (per each): $1.43 - $2.23

8 mg (per each): $2.01

16 mg (per each): $3.11 - $3.54

32 mg (per each): $4.62 - $5.18

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Adrelan (PH);
  • Advantan (MX);
  • Adventan (ES);
  • Cipridanol (PY);
  • Comedrol (ID);
  • Cryosolona (MX);
  • Depo Medrol (AE, BH, JO, KW, LB, QA, SA);
  • Depo-Medrol (BB, EG, ET, HR, IS, LU, LV, MX, NO, SI, SK, UA, VN, ZW);
  • Depo-Medrone (IE, MT);
  • Epizolone-Depot (ET);
  • Flason (ID);
  • Flumethyl (ID);
  • Lexcomet (ID);
  • Lexxema (ES);
  • M-Nisol (LK);
  • M-Prednihexal (DE);
  • Meapron (KR);
  • Medason (HK);
  • Medexa (VN);
  • Medisolu (KR);
  • Medixon (ID, MY, PH);
  • Medlon (VN);
  • Mednin (TW);
  • Medrate (DE);
  • Medrol (AE, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HN, HR, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KR, KW, LT, LU, LV, LY, MT, NI, NL, NO, NZ, OM, PA, PH, PL, PT, QA, RO, RU, SA, SE, SI, SK, SR, SV, SY, TT, UA, VE, YE, ZA);
  • Medrone (GB);
  • Melsone (IN);
  • Menisone (TW);
  • Mepresone (PH);
  • Mesolone (KR);
  • Metcor (ID);
  • Metcort (PH);
  • Methylon (KR);
  • Methylprednisolone David Bull (LU);
  • Methysol (KR);
  • Metrite (LK);
  • Metypred (UA);
  • Neo-Drol (LK);
  • Nisolon-M (KR);
  • Predlitem (MX);
  • Prednivex (LK, PH);
  • Prednol (TR);
  • Prednox (PH);
  • Prena (KR);
  • Pretilon (ID);
  • Prolon (ID);
  • Sanexon (ID, LK);
  • Sol-U-Pred (LK);
  • Sologen (KR);
  • Solomet (FI);
  • Solu Medrol (BF, BJ, CI, ET, GH, GM, GN, KE, LK, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);
  • Solu-Medon (VN);
  • Solu-Medrol (AE, AU, BB, BG, BH, CL, CN, CR, CY, DO, EG, GT, HK, HN, HR, IS, JO, JP, KW, LB, LT, LU, LV, MX, MY, NI, PA, PK, QA, RO, SA, SI, SK, SV, TH, TR, UA, UY);
  • Solu-Medrone (IE, MT);
  • Solu-Moderin (ES);
  • Solu-Pred (MY);
  • Somidex (TH);
  • Sonicor (ID);
  • Thimelon (ID);
  • Thylmedi (VN);
  • Tisolon-4 (ID);
  • Tropidrol (ID);
  • Urbason (AT, DE, EG, ES, HR, NL);
  • Urbason Retard (IT);
  • Yalone (ID)


For country abbreviations used in Lexicomp (show table)
  1. Abraham E, Evans T. Corticosteroids and Septic Shock [editorial]. JAMA. 2002;288(7):886-887. [PubMed 12186608]
  2. Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs. 2006;66(9):1191-1207. [PubMed 16827597]
  3. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  4. Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics. 2007;119(3):e778-782. [PubMed 17308245]
  5. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  6. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):118-125. [PubMed 12870721]
  7. American Academy of Pediatrics (AAP). What is the case definition of multisystem inflammatory syndrome in children (MIS-C)? Updated November 15, 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
  8. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456. [PubMed 29266076]
  9. American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 776: Immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295. doi:10.1097/AOG.0000000000003176 [PubMed 30913201]
  10. American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetrician-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed August 1, 2022.
  11. American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published January 2021. Accessed June 22, 2021.
  12. Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol. 2002;24(7):540-544. doi:10.1097/00043426-200210000-00008 [PubMed 12368690]
  13. Anderson GG, Rotchell Y, Kaiser DG. Placental Transfer of Methylprednisolone Following Maternal Intravenous Administration. Am J Obstet Gynecol. 1981;140(6):699-701. [PubMed 7020419]
  14. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  15. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017;45(12):2078-2088. doi:10.1097/CCM.0000000000002737 [PubMed 28938253]
  16. Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010;19(8):965-973. doi:10.1177/0961203310366855 [PubMed 20581019]
  17. Arnold DM, Cuker A, Kelton JG. Initial treatment of immune thrombocytopenia (ITP) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 8, 2022.
  18. Asero R. Now-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 23, 2021.
  19. Bahat E, Akkaya BK, Akman S, Karpuzoglu G, Guven AG. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis. J Nephrol. 2007;20(2):234-245. [PubMed 17514629]
  20. Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489-502. doi:10.1016/j.rdc.2017.04.013 [PubMed 28711148]
  21. Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lauque D, Charpentier S. Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial. Ann Emerg Med. 2018;71(1):125-131.e1. doi:10.1016/j.annemergmed.2017.03.006 [PubMed 28476259]
  22. Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982;101(1):137-141. [PubMed 7045314]
  23. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010;24(3):195-210. doi:10.1016/j.tmrv.2010.03.002 [PubMed 20656187]
  24. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-1021. doi:10.1007/s00467-017-3583-x [PubMed 28191596]
  25. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. doi:10.1183/13993003.04079-2020 [PubMed 34140301]
  26. Benson CA, Kaplan JE, Masur H, et al. Treating Opportunistic Infections Among HIV-Exposed and Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/IDSA. MMWR Recomm Rep. 2004;53(RR-15):1-112. [PubMed 15841069]
  27. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036 [PubMed 24766875]
  28. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Disease Society of America (IDSA), Guidelines on the treatment and management of patients with COVID-19. Published April 11, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated June 29, 2022. Accessed August 10, 2022.
  29. Boz C, Terzi M, Zengin Karahan S, Sen S, Sarac Y, Emrah Mavis M. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Mult Scler. 2018;24(9):1205-1211. doi:10.1177/1352458517717806 [PubMed 28649909]
  30. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322(20):1405-1411. [PubMed 2278545]
  31. Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992;76(1):23-31 [PubMed 1727165]
  32. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg. 1998;89(5):699-706. [PubMed 9817404]
  33. Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1084. doi:10.1212/NXI.0000000000001084 [PubMed 34607912]
  34. Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 25, 2021.
  35. Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014;113(6):599-608. doi: 10.1016/j.anai.2014.10.007. [PubMed 25466802]
  36. Canibaño B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess. 2020;9(1):20-36. doi:10.1080/21556660.2020.1721507 [PubMed 32128285]
  37. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472 [PubMed 33204386]
  38. Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician. 2002;66(2):283-288. [PubMed 12152964]
  39. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110(9):685-690. [PubMed 2648927]
  40. Carpenter PA, Macmillan ML, "Management of Acute Graft-Versus-Host Disease in Children," Pediatr Clin North Am, 2010, 57(1):273-95. [PubMed 20307721]
  41. Carroll CL, Sala KA. Pediatric status asthmaticus. Crit Care Clin. 2013;29(2):153-166. doi:10.1016/j.ccc.2012.12.001 [PubMed 23537669]
  42. Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2021.
  43. Cattalini M, Taddio A, Bracaglia C, et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Ital J Pediatr. 2021;47(1):24. doi:10.1186/s13052-021-00980-2 [PubMed 33557873]
  44. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  45. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  46. Chalhoub NE, Wenderfer SE, Levy DM, et al. International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis. Arthritis Rheumatol. Published online July 19, 2021. doi:10.1002/art.41930 [PubMed 34279063]
  47. Chapelon-Abric C, Sene D, Saadoun D, et al. Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors. Arch Cardiovasc Dis. 2017;110(8-9):456-465. doi:10.1016/j.acvd.2016.12.014 [PubMed 28566197]
  48. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83(6):315-334. doi:10.1097/01.md.0000145367.17934.75 [PubMed 15525844]
  49. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc. 2020;9(3):393-398. [PubMed 32463092]
  50. Cicardi M, Aberer W, Banerji Aet al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. doi: 10.1111/all.12380. [PubMed 24673465]
  51. Clouser KN, Gadhavi J, Bhavsar SM, et al. Short term outcomes after MIS-C treatment. J Pediatric Infect Dis Soc. Published online November 19, 2020. [PubMed 33211859]
  52. Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639. [PubMed 25838326]
  53. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348(8):727-734. doi: 10.1056/NEJMra020529. [PubMed 12594318]
  54. Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):237-239. [PubMed 25691380]
  55. Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956. doi: 10.1016/j.healun.2010.05.034. [PubMed 20643330]
  56. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi:10.2165/00003088-200544010-00003 [PubMed 15634032]
  57. Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13(3):311-323. doi: 10.1007/s11940-011-0119-8. [PubMed 21365201]
  58. Dasgupta B, Borg FA, Hassan N, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-1597. doi: 10.1093/rheumatology/keq039a. [PubMed 20371504]
  59. Davenport MS, Newhouse JH. Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2021.
  60. Delaleu J, Destere A, Hachon L, Declèves X, Lloret-Linares C. Glucocorticoids dosing in obese subjects: a systematic review. Therapie. 2019;74(4):451-458. doi:10.1016/j.therap.2018.11.016 [PubMed 30928086]
  61. Depo-Medrol multi-dose vials (methylprednisolone acetate) [prescribing information]. New York, NY: Pfizer; June 2021.
  62. Depo-Medrol single-dose vials (methylprednisolone acetate) [prescribing information]. New York, NY: Pfizer; received June 2021.
  63. Depo-Medrol (methylprednisolone acetate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; February 2021.
  64. DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001-1010. [PubMed 22290637]
  65. Ditzian-Kadanoff R, Ellman MH. How safe is it? High dose intravenous methylprednisolone. IMJ Ill Med J. 1987;172(6):432-434. [PubMed 2892818]
  66. Docken WP. Treatment of giant cell arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019.
  67. Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19(2):106-114. doi:10.1136/practneurol-2018-002060 [PubMed 30612100]
  68. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther. 1991;49(5):536-549. doi:10.1038/clpt.1991.64 [PubMed 1827621]
  69. Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. Br J Anaesth. 2014;113(3):346-359. doi: 10.1093/bja/aeu154. [PubMed 24980425]
  70. Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol. 2016;263(5):981-990. doi:10.1007/s00415-016-8092-5 [PubMed 27007482]
  71. Ebato T, Ogata S, Ogihara Y, et al. The clinical utility and safety of a new strategy for the treatment of refractory Kawasaki Disease. J Pediatr. 2017;191:140-144. [PubMed 29173297]
  72. Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP. 1989;23(12):1019-1023. [PubMed 2690471]
  73. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med. 2004;30(1):18-32. doi: 10.1007/s00134-003-2059-6. [PubMed 14625670]
  74. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi:10.1136/annrheumdis-2020-216924 [PubMed 32220834]
  75. Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: Emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019.
  76. Fazelpour S, Sadek MM, Nery PB, et al. Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: a systematic review. J Am Heart Assoc. 2021;10(17):e021183. doi:10.1161/JAHA.121.021183 [PubMed 34472360]
  77. Fervenza FC, Leise MD, Roccatello D, Kyle RA. Mixed cryoglobulinemia syndrome: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 5, 2020.
  78. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006 [PubMed 31945371]
  79. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638-656. doi: 10.1002/mus.24566. [PubMed 25641317]
  80. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180 [PubMed 32391934]
  81. Forbess L, Bannykh S. Polyarteritis nodosa. Rheum Dis Clin North Am. 2015;41(1):33-46, vii. doi: 10.1016/j.rdc.2014.09.005. [PubMed 25399938]
  82. Furst DE, Saag KG. Determinants of glucocorticoid dosing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019a.
  83. Furst DE, Saag KG. Glucocorticoid withdrawal. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019b.
  84. Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2022.
  85. Garin EH, Sleasman JW, Richard GA, Iravani AA, Fennell RS. Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. Eur J Pediatr. 1986;145(5):380-383. [PubMed 3792382]
  86. Gereige RS, Barrios NJ. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both. P R Health Sci J. 2000;19(1):15-18. [PubMed 10761200]
  87. Giuliano JS Jr, Faustino EV, Li S, et al. Corticosteroid therapy in critically ill pediatric asthmatic patients. Pediatr Crit Care Med. 2013;14(5):467-470. doi:10.1097/PCC.0b013e31828a7451 [PubMed 23628833]
  88. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed September 24, 2021.
  89. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 Report. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed July 14, 2020.
  90. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2021 global strategy for prevention, diagnosis, and management of COPD. https://goldcopd.org/2021-gold-reports. Accessed December 7, 2021.
  91. Goedert JJ, Vitale F, Lauria C, et al. Risk Factors for Classical Kaposi's Sarcoma. J Natl Cancer Inst. 2002;94(22):1712-1718. [PubMed 12441327]
  92. Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014;122:455-464. doi: 10.1016/B978-0-444-52001-2.00020-0. [PubMed 24507531]
  93. Grissinger M. Medication errors: mix-ups with “medrols.” P T. 2007;32(8):417-419. https://www.ptcommunity.com/system/files/pdf/ptj3208417.pdf.
  94. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898 [PubMed 28877866]
  95. Guillén EL, Ruíz AM, Bugallo JB. Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. Am J Kidney Dis. 1998;32(2):E4. [PubMed 10074612]
  96. Gupta A, Gill A, Sharma M, Garg M. Multi-system inflammatory syndrome in a child mimicking Kawasaki disease. J Trop Pediatr. Published online August 10, 2020. [PubMed 32778886]
  97. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004;41(10):993-1000. [PubMed 15523124]
  98. Hashash JA, Regueiro M. Overview of medical management of high-risk, adult patients with moderate to severe Crohn disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 2, 2021.
  99. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. Arthritis Rheumatol. Published online February 3, 2022. doi:10.1002/art.42062 [PubMed 35118829]
  100. Hogan J, Godron A, Baudouin V, et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol. 2018;33(1):111-116. doi:10.1007/s00467-017-3767-4 [PubMed 28780657]
  101. Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. Neonatology. 2008;94(4):306-309. doi:10.1159/000151652 [PubMed 18784429]
  102. Honoré PM, Jacobs R, De Waele E, et al. What do we know about steroids metabolism and 'PK/PD approach' in AKI and CKD especially while on RRT--current status in 2014. Blood Purif. 2014;38(2):154-157. doi:10.1159/000368390 [PubMed 25471548]
  103. Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436 [PubMed 32678530]
  104. Hurlbert RJ, Hadley MN, Walters BC, et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery. 2013;72(suppl 2):93-105. [PubMed 23417182]
  105. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  106. Institute for Safe Medication Practices (ISMP). Do not let “depo-" medications be a depot for mistakes. https://www.ismp.org/resources/do-not-let-depo-medications-be-depot-mistakes. Updated March 24, 2016. Accessed October 7, 2019.
  107. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
  108. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  109. James C, Berstein JA. Current and future therapies for the treatment of histamine-induced angioedema. Expert Opin Pharmacother. 2017;18(3):253-262. doi: 10.1080/14656566.2017.1282461. [PubMed 28081650]
  110. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med. 2013;1:1-10. [PubMed 23546607]
  111. Jonat B, Gorelik M, Boneparth A, et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med. 2021;22(3):e178-e191. doi:10.1097/PCC.0000000000002598 [PubMed 33003176]
  112. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Semin Arthritis Rheum. 2016;46(1):133-141. doi:10.1016/j.semarthrit.2016.03.001 [PubMed 27105755]
  113. Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461. doi:10.1002/acr.21773 [PubMed 23024029]
  114. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021 [PubMed 34556256]
  115. Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163(2):521-526. [PubMed 23485027]
  116. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613-1620. [PubMed 22405251]
  117. Kotloff RM, Blosser S, Fulda GJ, et al; Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Donor Management Task Force. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations consensus statement. Crit Care Med. 2015;43(6):1291-1325. doi: 10.1097/CCM.0000000000000958. [PubMed 25978154]
  118. Kurtoğlu S, Sarıcı D, Akın MA, Daar G, Korkmaz L, Memur Ş. Fetal adrenal suppression due to maternal corticosteroid use: case report. J Clin Res Pediatr Endocrinol. 2011;3(3):160-162. doi:10.4274/jcrpe.v3i3.31 [PubMed 21911331]
  119. Lam DS, Fan DS, Ng JS, et al, "Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial," Clin Experiment Ophthalmol, 2005, 33(3):252-8. [PubMed 15932528]
  120. Le Page E, Veillard D, Laplaud DA, et al; COPOUSEP investigators; West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974-981. doi: 10.1016/S0140-6736(15)61137-0. [PubMed 26135706]
  121. Leonard MB, "Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease," Pediatrics, 2007, 119 Suppl 2:S166-74. [PubMed 17332238]
  122. Leonhard SE, Fritz D, Eftimov F, van der Kooi AJ, van de Beek D, Brouwer MC. Neurosarcoidosis in a tertiary referral center: a cross-sectional cohort study. Medicine (Baltimore). 2016;95(14):e3277. doi:10.1097/MD.0000000000003277 [PubMed 27057889]
  123. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27. [PubMed 29610508]
  124. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019. [PubMed 26505932]
  125. Lucas KG, Howrie DL, Phebus CK. Cardiorespiratory decompensation following methylprednisolone administration. Pediatr Hematol Oncol. 1993;10(3):249-255. [PubMed 8217541]
  126. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  127. Lui JK, Mesfin N, Tugal D, Klings ES, Govender P, Berman JS. Critical care of patients with cardiopulmonary complications of sarcoidosis. J Intensive Care Med. 2022;37(4):441-458. doi:10.1177/0885066621993041 [PubMed 33611981]
  128. Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med. 2012;40(5):1635-1644. doi: 10.1097/CCM.0b013e3182416ee7. [PubMed 22511141]
  129. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022 [PubMed 30658060]
  130. Marks SD and Tullus K, "Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis," Acta Paediatr, 2010, 99(7):967-74. [PubMed 20222881]
  131. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. doi: 10.1016/j.bbmt.2012.04.005. [PubMed 22510384]
  132. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):272-279. doi: 10.1111/ajt.12119. [PubMed 23465020]
  133. Mathes BM, Alguire PC. Intralesional corticosteroid injection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 5, 2020.
  134. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999. [PubMed 28356445]
  135. Medrol tablets (methylprednisolone) [prescribing information]. New York, NY: Pfizer; February 2019.
  136. Medrol (methylprednisolone) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; November 2019.
  137. Meduri G, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954-963. doi: 10.1378/chest.06-2100. [PubMed 17426195]
  138. Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x [PubMed 34143362]
  139. Merkel PA. Treatment and prognosis of polyarteritis nodosa. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 12, 2020.
  140. Methylprednisolone tablets [prescribing information]. Peapack, NJ: Greenstone LLC; July 2012.
  141. Methylprednisolone injectable suspension [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; July 2019.
  142. Methylprednisolone injectable suspension [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; September 2020.
  143. Methylprednisolone injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; December 2016.
  144. Methylprednisolone injection [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; October 2017.
  145. Meyer KC, Raghu G, Verleden GM, et al; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44(6):1479-1503. [PubMed 25359357]
  146. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019 [PubMed 31699837]
  147. Milad MA, Ludwig EA, Lew KH, Kohli RK, Jusko WJ. The pharmacokinetics and pharmacodynamics of methylprednisolone in chronic renal failure. Am J Ther. 1994;1(1):49-57. doi:10.1097/00045391-199406000-00009 [PubMed 11835067]
  148. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375-383. [PubMed 22162255]
  149. Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr. 2008;167(10):1119-1123. [PubMed 18175148]
  150. Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19(11):1232-1236. doi:10.1007/s00467-004-1584-z [PubMed 15322892]
  151. Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289-298. doi: 10.1182/blood-2016-09-719773. [PubMed 27799164]
  152. Muraro A, Roberts G, Worm M, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026-1045. doi: 10.1111/all.12437. [PubMed 24909803]
  153. Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol Scand Suppl. 2009;(189):73-80. doi: 10.1111/j.1600-0404.2009.01213.x. [PubMed 19566504]
  154. Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. J Investig Allergol Clin Immunol. 2016;26(1):1-7. [PubMed 27012010]
  155. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124 [PubMed 33144515]
  156. National Asthma Education and Prevention Program (NAEPP). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart Lung, and Blood Institute; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Published October 2007. Accessed June 15, 2016.
  157. National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/. Updated February 24, 2022a. Accessed March 7, 2022.
  158. National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines: Therapeutic management of patients with COVID-19. https://www.covid19treatmentguidelines.nih.gov/therapeutic-management. Updated August 8, 2022b. Accessed August 9, 2022.
  159. National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. Clinical guideline [CG186]. https://www.nice.org.uk/guidance/cg186. Published October 2014. Accessed October 7, 2016.
  160. Novitzky D, Mi Z, Collins JF, Cooper DK. Increased procurement of thoracic donor organs after thyroid hormone therapy. Semin Thorac Cardiovasc Surg. 2015;27(2):123-132. doi: 10.1053/j.semtcvs.2015.06.012. [PubMed 26686437]
  161. Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation. 2014;98(10):1119-1127. doi: 10.1097/TP.0000000000000187. [PubMed 25405914]
  162. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129(1):e17-23. [PubMed 22144699]
  163. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181-185. [PubMed 18446365]
  164. Olek MJ, Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 26, 2021.
  165. Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone Excretion in Human Milk. J Pediatr. 1985;106(6):1008-1011. [PubMed 3998938]
  166. Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. Published online February 1, 2021. [PubMed 33523115]
  167. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215-1224. [PubMed 9596297]
  168. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449-460. doi:10.1093/qjmed/hcp042 [PubMed 19383611]
  169. Peña A, Bravo J, Melgosa M, et al. Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy. Pediatr Nephrol. 2007;22(11):1875-1880. doi:10.1007/s00467-007-0567-2 [PubMed 17876609]
  170. Peppercorn MA, Farrell RJ. Management of the hospitalized adult patient with severe colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019.
  171. Perlman DM, Sudheendra MT, Furuya Y, et al. Clinical presentation and treatment of high-risk sarcoidosis. Ann Am Thorac Soc. 2021;18(12):1935-1947. doi:10.1513/AnnalsATS.202102-212CME [PubMed 34524933]
  172. Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. doi: 10.1111/cea.12494. [PubMed 25711134]
  173. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812 [PubMed 31770441]
  174. Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68. doi:10.7326/M16-0570 [PubMed 27802508]
  175. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707 [PubMed 27457514]
  176. Roberts WN. Intraarticular and soft tissue injections: What agent(s) to inject and how frequently? Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 3, 2021.
  177. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003a;75(4):482-487. doi:10.1097/01.TP.0000045683.85282.93 [PubMed 12605114]
  178. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003b;75(8):1336-1341. doi:10.1097/01.TP.0000062839.58826.6D [PubMed 12717226]
  179. Rouster-Stevens KA, Gursahaney A, Ngai KL, et al. Pharmacokinetic Study of Oral Prednisolone Compared With Intravenous Methylprednisolone in Patients With Juvenile Dermatomyositis. Arthritis Rheum. 2008;59(2):222-6. [PubMed 18240180]
  180. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152 [PubMed 30840605]
  181. Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN Working Group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168-173. doi:10.1038/bmt.2013.107 [PubMed 23892326]
  182. Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). Obstet Gynecol. 2020;136(4):823-826. doi:10.1097/AOG.0000000000004103 [PubMed 32769659]
  183. Safari HR, Fassett MJ, Souter IC, et al. The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. Am J Obstet Gynecol. 1998;179(4):921-924. [PubMed 9790371]
  184. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology (ACR) guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529‐556. doi:10.1002/art.41191 [PubMed 32090480]
  185. Sax PE. Treatment and prevention of Pneumocystis infection in HIV-infected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 12, 2020.
  186. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017 [PubMed 32001253]
  187. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  188. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25(5):899-903. doi:10.1007/s00467-009-1417-1 [PubMed 20108003]
  189. Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. Nephron. 1977;18(4):208-211. doi:10.1159/000180830 [PubMed 854143]
  190. Siegel MD, Siemieniuk R. Acute respiratory distress syndrome: Supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 17, 2020.
  191. Simons FE, Ardusso LR, Bilò MB; World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37. doi: 10.1097/WOX.0b013e318211496c. [PubMed 23268454]
  192. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32. doi:10.1186/s40413-015-0080-1 [PubMed 26525001]
  193. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113(2):175-194. doi:10.1038/ajg.2017.469 [PubMed 29336434]
  194. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335. [PubMed 23868909]
  195. Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506. doi:10.1002/bdra.23248 [PubMed 24777675]
  196. Solu-Medrol (methylprednisolone sodium succinate) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; October 2021.
  197. Solu-Medrol and Solu-Medrol Act-O-Vials (methylprednisolone sodium succinate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; February 2022.
  198. Son MBF, Murray N, Friedman K, et al; Overcoming COVID-19 Investigators. Multisystem inflammatory syndrome in children—initial therapy and outcomes. N Engl J Med. 2021;385(1)23-34. doi:10.1056/NEJMoa2102605 [PubMed 34133855]
  199. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865 [PubMed 30272171]
  200. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613-1619. [PubMed 9751093]
  201. Stein CA, Levin R, Given R, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study. Urol Oncol. 2018;36(2):81.e9-81.e16. doi:10.1016/j.urolonc.2017.10.018 [PubMed 29150328]
  202. Steinberg KP, Hudson LD, Goodman RB; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684. doi:10.1056/NEJMoa051693 [PubMed 16625008]
  203. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol. 2004;17(3):311-316. doi:10.1097/00019052-200406000-00013 [PubMed 15167067]
  204. Stoller JK. Management of exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2019.
  205. Strijbos E, Coenradie S, Touw DJ, Aerden L. High-dose methylprednisolone for multiple sclerosis during lactation: concentrations in breast milk. Mult Scler. 2015;21(6):797-798. [PubMed 25583837]
  206. Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76(1):4-20. doi:10.1136/thoraxjnl-2019-214348 [PubMed 33268456]
  207. Thomas CF Jr, Limper AH. Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 24, 2019.
  208. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012;32(3):645-653. doi:10.1007/s00296-010-1697-6 [PubMed 21132302]
  209. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. doi:10.1007/s00467-020-04519-1 [PubMed 32382828]
  210. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257-291. [PubMed 30044357]
  211. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed May 4, 2020.
  212. US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines. Updated November 18, 2021. Accessed December 7, 2021.
  213. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new. Updated March 19, 2021. Accessed December 7, 2021.
  214. Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16(3):289-296. doi:10.1111/j.1468-1331.2008.02409.x [PubMed 19170748]
  215. von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988;296(6617):249-250. doi:10.1136/bmj.296.6617.249-a [PubMed 2449258]
  216. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.
  217. World Health Organization (WHO). Corticosteroids for COVID-19: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Published September 2, 2020. Accessed December 9, 2020.
  218. Yonsa (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2018.
  219. Younger RE, Gerber PS, Herrod HG, Cohen RM, Crawford LV. Intravenous methylprednisolone efficacy in status asthmaticus of childhood. Pediatrics. 1987;80(2):225-230. [PubMed 3302924]
  220. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547-1554. doi:10.3324/haematol.2014.114561 [PubMed 25271314]
  221. Zeiser, R. Treatment of acute graft-versus-host disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 27, 2022.
  222. Zengin Karahan S, Boz C, Terzi M, et al. Methylprednisolone concentrations in breast milk and serum of patients with multiple sclerosis treated with IV pulse methylprednisolone. Clin Neurol Neurosurg. 2020;197:106118. doi:10.1016/j.clineuro.2020.106118 [PubMed 32768896]
  223. Zhang H, Wang Z, Dong LQ, Guo YN. Children with steroid-resistant nephrotic syndrome: long-term outcomes of sequential steroid therapy. Biomed Environ Sci. 2016;29(9):650-655. doi:10.3967/bes2016.087 [PubMed 27806747]
  224. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397. [PubMed 29336054]
  225. Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 5, 2021.
Topic 9639 Version 554.0